Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE February 17, 2017

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia | Read more 


February 8, 2017

CYTOVIA: Building a Leading Immuno-Oncology Company | Read more 


EVENT January 27, 2017

Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events